Abstract
The first clinical study of a synthetic peptide-based vaccine against the Epstein-Barr virus (EBV) is now underway. Researchers are hopeful that the vaccine, which contains a cytotoxic T-lymphocyte (CTL) epitope, may protect against EBV immunopathology.Inpharma spoke to Dr Andreas Suhrbier, from the Queensland Institute of Medical Research, Brisbane, Australia, about the current phase I trial and the potential applications for an EBV vaccine in protecting against infectious mononucleosis (glandular fever) and the development of post-transplant lymphoproliferative disease (PTLD).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
